A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone.
Animals
Antibodies, Neutralizing
/ immunology
Antigens
/ genetics
Aquifex
Bacteria
/ enzymology
Bacterial Proteins
/ genetics
Betacoronavirus
/ isolation & purification
COVID-19
Coronavirus Infections
Ferritins
/ genetics
Helicobacter pylori
/ metabolism
Humans
Mice
Multienzyme Complexes
/ genetics
Nanoparticles
/ chemistry
Neutralization Tests
Pandemics
Pneumonia, Viral
Protein Multimerization
Recombinant Proteins
/ biosynthesis
SARS-CoV-2
Spike Glycoprotein, Coronavirus
/ genetics
Surface Properties
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 10 2020
23 10 2020
Historique:
received:
11
06
2020
accepted:
25
09
2020
entrez:
24
10
2020
pubmed:
25
10
2020
medline:
5
11
2020
Statut:
epublish
Résumé
Antigens displayed on self-assembling nanoparticles can stimulate strong immune responses and have been playing an increasingly prominent role in structure-based vaccines. However, the development of such immunogens is often complicated by inefficiencies in their production. To alleviate this issue, we developed a plug-and-play platform using the spontaneous isopeptide-bond formation of the SpyTag:SpyCatcher system to display trimeric antigens on self-assembling nanoparticles, including the 60-subunit Aquifex aeolicus lumazine synthase (LuS) and the 24-subunit Helicobacter pylori ferritin. LuS and ferritin coupled to SpyTag expressed well in a mammalian expression system when an N-linked glycan was added to the nanoparticle surface. The respiratory syncytial virus fusion (F) glycoprotein trimer-stabilized in the prefusion conformation and fused with SpyCatcher-could be efficiently conjugated to LuS-SpyTag or ferritin-SpyTag, enabling multivalent display of F trimers with prefusion antigenicity. Similarly, F-glycoprotein trimers from human parainfluenza virus-type 3 and spike-glycoprotein trimers from SARS-CoV-2 could be displayed on LuS nanoparticles with decent yield and antigenicity. Notably, murine vaccination with 0.08 µg of SARS-CoV-2 spike-LuS nanoparticle elicited similar neutralizing responses as 2.0 µg of spike, which was ~ 25-fold higher on a weight-per-weight basis. The versatile platform described here thus allows for multivalent plug-and-play presentation on self-assembling nanoparticles of trimeric viral antigens, with SARS-CoV-2 spike-LuS nanoparticles inducing particularly potent neutralizing responses.
Identifiants
pubmed: 33097791
doi: 10.1038/s41598-020-74949-2
pii: 10.1038/s41598-020-74949-2
pmc: PMC7584627
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antigens
0
Bacterial Proteins
0
Multienzyme Complexes
0
Recombinant Proteins
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
6,7-dimethyl-8-ribityllumazine synthase
89287-46-7
Ferritins
9007-73-2
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
18149Commentaires et corrections
Type : UpdateOf
Références
N Engl J Med. 2020 Oct 15;383(16):1544-1555
pubmed: 32722908
mBio. 2019 Feb 26;10(1):
pubmed: 30808695
Front Immunol. 2019 Dec 12;10:2931
pubmed: 31921185
Vaccine. 2019 Oct 8;37(43):6405-6414
pubmed: 31515145
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
J Virol. 2003 May;77(10):5889-901
pubmed: 12719582
Nature. 2013 Jul 4;499(7456):102-6
pubmed: 23698367
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Science. 2016 Mar 25;351(6280):1458-63
pubmed: 27013733
N Engl J Med. 2015 Jul 30;373(5):415-27
pubmed: 26172429
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
J Struct Biol. 2007 Jan;157(1):38-46
pubmed: 16859925
Nanomedicine. 2019 Feb;16:69-78
pubmed: 30529790
Cell. 2020 Nov 25;183(5):1367-1382.e17
pubmed: 33160446
Malar J. 2016 Nov 8;15(1):545
pubmed: 27825348
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
mBio. 2017 Feb 28;8(1):
pubmed: 28246356
Nature. 2019 Jun;570(7762):468-473
pubmed: 31142836
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
J Mol Biol. 2009 Jul 3;390(1):83-98
pubmed: 19427319
Sci Rep. 2016 Jan 19;6:19234
pubmed: 26781591
J Virol. 2014 Dec;88(24):14002-16
pubmed: 25253346
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
J Virol. 2006 Oct;80(19):9896-8
pubmed: 16973594
Nat Commun. 2015 Jul 28;6:7712
pubmed: 26218507
PLoS One. 2008 Jun 25;3(6):e2547
pubmed: 18575629
J Nanobiotechnology. 2016 Apr 27;14:30
pubmed: 27117585
Comput Struct Biotechnol J. 2015 Nov 26;14:58-68
pubmed: 26862374
J Virol. 2018 Oct 29;92(22):
pubmed: 30185594
Mol Ther. 2016 May;24(5):1003-12
pubmed: 26686385
Cell. 2019 Mar 7;176(6):1420-1431.e17
pubmed: 30849373
J Mol Biol. 1994 Sep 30;242(4):470-86
pubmed: 7932704
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E690-7
pubmed: 22366317
Curr Opin Chem Biol. 2015 Dec;29:94-9
pubmed: 26517567
Cell. 2016 May 5;165(4):813-26
pubmed: 27114034
PLoS Med. 2006 Jul;3(7):e237
pubmed: 16796401
Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):12265-12270
pubmed: 30420505
Immunity. 2018 Aug 21;49(2):301-311.e5
pubmed: 30076101
Cell. 2018 Mar 8;172(6):1319-1334
pubmed: 29522750
Nat Med. 2015 Sep;21(9):1065-70
pubmed: 26301691
J Struct Biol. 2005 Oct;152(1):36-51
pubmed: 16182563
Cell Rep. 2020 Oct 27;33(4):108322
pubmed: 33091382
Sci Immunol. 2020 May 1;5(47):
pubmed: 32358170
J Struct Biol. 1996 Jan-Feb;116(1):190-9
pubmed: 8742743
Lancet. 2015 Jul 4;386(9988):31-45
pubmed: 25913272
Curr Opin Immunol. 2019 Aug;59:57-64
pubmed: 31029910
Nat Struct Mol Biol. 2016 Sep;23(9):811-820
pubmed: 27478931
J Mol Biol. 2001 Mar 9;306(5):1099-114
pubmed: 11237620
Science. 2013 Nov 1;342(6158):592-8
pubmed: 24179220
Nat Commun. 2016 Jun 28;7:12041
pubmed: 27349934
J Struct Biol. 2012 Dec;180(3):519-30
pubmed: 23000701